News

Fierce Pharma11d
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...
Verywell Health on MSN3d
Enhertu Shows Promise as First-Line Treatment for Metastatic Breast Cancer
A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...
Morningstar7d
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Since 2018, anti-PD-1 monoclonal antibodies have been approved for the second-line ... the treatment of melanoma, perioperative treatment of NSCLC, treatment of RCC and treatment of TNBC.
Applied Clinical Trials Online11d
DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly Improves Survival in HER2-Positive Metastatic Breast Cancer
In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...
TMCnet7d
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Since 2018, anti-PD-1 monoclonal antibodies have been approved for the second-line or later treatment ... in the NRDL for the treatment of melanoma, perioperative treatment of NSCLC, treatment of RCC ...